8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
Published . Updated .
Key takeaways
- 8-K - InMed Pharmaceuticals filed an 8-K with the SEC on Nov 3 (a notice of a material company event).
- Exposed: INM
- Market reaction: INM −89.3% after two sessions
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
8-K - InMed Pharmaceuticals filed an 8-K with the SEC on Nov 3 (a notice of a material company event).
Directly affected
- INM InMed Pharmaceuticals
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story.
- LLY Eli Lilly and+15.5% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- JNJ Johnson & Johnson+0.1% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- PFE Pfizer+4.0% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- MRK Merck+3.5% 30d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| INM | -5.33% | -5.33% | base | +7.10% | -89.29% | -89.29% | after close |
| XLV | -2.31% | +0.48% | base | +3.08% | +0.65% | +0.47% | after close |
| XBI | +1.67% | +0.67% | base | +2.69% | -4.21% | -1.76% | after close |
| LLY | -8.42% | +0.54% | base | +0.62% | -2.48% | -3.88% | after close |
| JNJ | +1.93% | +2.66% | base | +3.82% | +2.34% | +3.82% | after close |
| PFE | -1.67% | +1.73% | base | +2.70% | -0.33% | -1.98% | after close |
| MRK | -2.47% | +3.37% | base | +3.94% | +1.84% | +1.45% | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Filed: 2026-11-03 AccNo: 0001062993-26-005723 Size: 341 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Source: sec-edgar
InMed Pharmaceuticals (INM) since this story, compared with the market
Since the first closing price after “8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer),” InMed Pharmaceuticals (INM) is +647.22%.
| Company | When | Move | Status |
|---|---|---|---|
| InMed Pharmaceuticals (INM) | that day | +7.10% | final price |
| InMed Pharmaceuticals (INM) | the next day | -89.29% | final price |
| InMed Pharmaceuticals (INM) | two days later | -89.29% | final price |
| InMed Pharmaceuticals (INM) | three days earlier | -5.33% | final price |
| InMed Pharmaceuticals (INM) | five days earlier | -5.33% | final price |
| JNJ | that day | +3.82% | final price |
| JNJ | the next day | +2.34% | final price |
| JNJ | two days later | +3.82% | final price |
| JNJ | three days earlier | +2.66% | final price |
| JNJ | five days earlier | +1.93% | final price |
| LLY | that day | +0.62% | final price |
| LLY | the next day | -2.48% | final price |
| LLY | two days later | -3.88% | final price |
| LLY | three days earlier | +0.54% | final price |
| LLY | five days earlier | -8.42% | final price |
| MRK | that day | +3.94% | final price |
| MRK | the next day | +1.84% | final price |
| MRK | two days later | +1.45% | final price |
| MRK | three days earlier | +3.37% | final price |
| MRK | five days earlier | -2.47% | final price |
| PFE | that day | +2.70% | final price |
| PFE | the next day | -0.33% | final price |
| PFE | two days later | -1.98% | final price |
| PFE | three days earlier | +1.73% | final price |
| PFE | five days earlier | -1.67% | final price |
| XBI | that day | +2.69% | final price |
| XBI | the next day | -4.21% | final price |
| XBI | two days later | -1.76% | final price |
| XBI | three days earlier | +0.67% | final price |
| XBI | five days earlier | +1.67% | final price |
| XLV | that day | +3.08% | final price |
| XLV | the next day | +0.65% | final price |
| XLV | two days later | +0.47% | final price |
| XLV | three days earlier | +0.48% | final price |
| XLV | five days earlier | -2.31% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 34 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 39 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 56 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 74 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 40 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 76 days before publication. Filed 9 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around InMed Pharmaceuticals (INM)
Companies tied to this story
- INM InMed Pharmaceuticals
InMed Pharmaceuticals (INM) is linked, with no stored direction, high confidence in the 3 Nov 2026 story “8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer).” Reason on file: SEC 8-K filing -> direct issuer disclosure -> INM
How “8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)” reaches InMed Pharmaceuticals (INM)
“8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)” (3 Nov 2026) reaches InMed Pharmaceuticals (INM) through this story.
InMed Pharmaceuticals (INM) is on the page because SEC 8-K filing -> direct issuer disclosure -> INM
Dates in the story, and the InMed Pharmaceuticals (INM) price range
INM traded between 1.68 and 15.41 across 3 sessions. The latest close on file is 13.45.
What the saved facts support for InMed Pharmaceuticals (INM)
14 out of 100
“8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.